A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
GlaxoSmithKline
Novartis
Elicio Therapeutics
Guardant Health, Inc.
ModeX Therapeutics, An OPKO Health Company
Tempus AI
Revolution Medicines, Inc.
DxTerity Diagnostics
UTC Therapeutics Inc.
Corvus Pharmaceuticals, Inc.
Klus Pharma Inc.
MacroGenics
Stryker Orthopaedics
SpeciCare
SPGO Research Mannheim GmbH
INSYS Therapeutics Inc